Literature DB >> 1281469

Localization of agonist and antagonist binding domains of the human neurokinin-1 receptor.

T M Fong1, R R Huang, C D Strader.   

Abstract

To identify the molecular determinants of ligand-receptor interactions, the extracellular domain of the human neurokinin-1 receptor was systematically substituted with the corresponding sequences from the other two neurokinin receptor subtypes. Three residues within the first extracellular segment and 2 residues of the second segment are required for the optimal binding of all three natural peptide agonists. The divergent nature of 4 of the 5 residues supports the hypothesis that the peptide binding site on the neurokinin-1 receptor is not highly conserved in the other two receptor subtypes. In contrast, substitution of part of the third extracellular segment and the fourth extracellular segment with the corresponding amino acids of the human neurokinin-3 receptor results in an increase in neurokinin B affinity without affecting substance P binding, suggesting that the two peptides do not interact with the same set of functional groups on the receptor. Among the four extracellular regions, only parts of the third and fourth segments affect the binding of the quinuclidine antagonist L-703,606, and these two regions may partially account for the neurokinin-1 receptor subtype specificity of this non-peptide antagonist. These studies demonstrate that both the extracellular and transmembrane domains of the neurokinin-1 receptor are involved in the binding of substance P and related peptides.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1281469

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Mutational analysis and molecular modeling of the nonapeptide hormone binding domains of the [Arg8]vasotocin receptor.

Authors:  H Hausmann; A Richters; H J Kreienkamp; W Meyerhof; H Mattes; K Lederis; H Zwiers; D Richter
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Molecular Architecture of G Protein-Coupled Receptors.

Authors:  A Michiel van Rhee; Kenneth A Jacobson
Journal:  Drug Dev Res       Date:  1996-01-01       Impact factor: 4.360

3.  Purification of a rat neurotensin receptor expressed in Escherichia coli.

Authors:  J Tucker; R Grisshammer
Journal:  Biochem J       Date:  1996-08-01       Impact factor: 3.857

Review 4.  Modes of peptide binding in G protein-coupled receptors.

Authors:  M Berthold; T Bartfai
Journal:  Neurochem Res       Date:  1997-08       Impact factor: 3.996

5.  Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1: implications for the ligand-binding site.

Authors:  F M Dautzenberg; S Wille; R Lohmann; J Spiess
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

6.  Genetic transfer of a nonpeptide antagonist binding site to a previously unresponsive angiotensin receptor.

Authors:  H Ji; W Zheng; Y Zhang; K J Catt; K Sandberg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

7.  Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding. Analysis of chimeric A1/A3 adenosine receptors.

Authors:  M E Olah; K A Jacobson; G L Stiles
Journal:  J Biol Chem       Date:  1994-10-07       Impact factor: 5.157

8.  Functional interaction between losartan and central tachykinin NK3 receptors in the conscious rat.

Authors:  P Picard; L Chrétien; R Couture
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

9.  Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors.

Authors:  S J Siciliano; T E Rollins; J DeMartino; Z Konteatis; L Malkowitz; G Van Riper; S Bondy; H Rosen; M S Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

10.  Molecular basis for high affinity and selectivity of peptide antagonist, Bantag-1, for the orphan BB3 receptor.

Authors:  Taichi Nakamura; Irene Ramos-Álvarez; Tatiana Iordanskaia; Paola Moreno; Samuel A Mantey; R T Jensen
Journal:  Biochem Pharmacol       Date:  2016-06-23       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.